BioSpace News Archive

atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, provided key clinical pipeline and corporate updates.

Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.

Compugen Ltd. today announced that the first patient has been dosed in the triple combination proof-of-concept study evaluating COM701.

Lavie Bio Ltd. today announced in that its management will be sponsoring and participating at the World Agri-Tech Conference in San Francisco, taking place between March 14-15, 2023.

Kezar Life Sciences, Inc. today announced that it will host a virtual Research and Development (R&D) Day on Wednesday, March 22, 2023 at 4:30 pm ET/1:30 pm PT.

After acquiring substantially all assets of BERG, LLC at the beginning of 2023, BPGbio, Inc, a leading AI-powered biopharma with a mission to reimagine biology for humanity, announced today the appointment of four key executives.

Corentec, a forward-thinking medical device company focused on developing solutions for the orthopedic market, will be showcasing its latest products at the American Academy of Orthopedic Surgeons 2023 Conference from March 7 to March 11, 2023, in the Venetian Expo booth # 5027.

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumors in heavily pretreated patients.

Zevra Therapeutics, Inc. today announced that Richard W. Pascoe, the Company’s Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference on Monday, March 13, 2023, at 2:00 p.m. PT.

Relay Therapeutics, Inc. today announced that initial clinical data from the ReDiscover trial for RLY-2608 have been selected for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023.